title: Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.
authors.forename: Lingkun
authors.initials: L
authors.lastname: Kong
authors.forename: Helen A
authors.initials: HA
authors.lastname: Mintz-Hittner
authors.forename: Rebecca L
authors.initials: RL
authors.lastname: Penland
authors.forename: Francis L
authors.initials: FL
authors.lastname: Kretzer
authors.forename: Patricia
authors.initials: P
authors.lastname: Chévez-Barrios
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D053148:Caspase 3 / Q000378:metabolism; D017809:Fatal Outcome; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007267:Injections; D008297:Male; D012178:Retinopathy of Prematurity / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D053148:Caspase 3